<DOC>
	<DOCNO>NCT03034317</DOCNO>
	<brief_summary>The purpose research study collect information use , safety , effectiveness NeuRx DPSÂ® ALS patient .</brief_summary>
	<brief_title>NeuRx Diaphram Pacing System ( DPS ) Use Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>Characterize safety benefit on-label Humanitarian Device Exemption ( HDE ) use DPS patient ALS initiate noninvasive ventilation ( NIV ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Age 21 old Familial sporadic ALS diagnose possible , laboratorysupported probable , probable , definite accord World Federation Neurology El Escorial criterion Bilateral phrenic nerve function clinically acceptable demonstrated bilateral diaphragm movement fluoroscopic sniff test phrenic nerve conduction study Chronic hypoventilation document least one following : MIP ( respiratory muscle strength ) less 60 cmH2O , Forced Vital Capacity ( FVC ) less 50 % predict , PaCO2 great equal 45 mmHg , Nocturnal SaO2 ( arterial oxygen saturation ) less equal 88 % least five continuous minute Initiation noninvasive ventilation time enrollment Suitable surgical candidate receive diaphragm pace stimulation Negative pregnancy test female participant childbearing potential ( treatment group ) Informed consent patient designate representative FVC le 45 % predict within 10 day prior surgery . Participation simultaneous therapeutic clinical trial could affect safety benefit outcome study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diaphragm Pacing</keyword>
</DOC>